Cardio Diagnostics to host investor call on heart disease test
Cardio Diagnostics (CDIO) will host an investor call on Dec 10, 2026, to discuss its cardiovascular disease detection tech, including data on NOCAD detection and FDA Breakthrough Device designation. The company will also update on its commercial tests, studies, and international expansion to India. CDIO uses epigenetics, genetics, and AI for disease prevention and detection.


